|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
stimulant
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:approvedBy
|
1955 (US)
|
|
gptkbp:ATCCode
|
N06BA04
|
|
gptkbp:brand
|
gptkb:Daytrana
gptkb:Quillivant_XR
gptkb:Ritalin
gptkb:Concerta
gptkb:Aptensio_XR
gptkb:Biphentin
Metadate
|
|
gptkbp:CASNumber
|
113-45-1
|
|
gptkbp:contraindication
|
glaucoma
Tourette syndrome
severe anxiety
tics
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Class_B_(UK)
gptkb:Schedule_III_(Canada)
gptkb:Schedule_II_(US)
|
|
gptkbp:discoveredBy
|
gptkb:Leandro_Panizzon
|
|
gptkbp:discoveredIn
|
1944
|
|
gptkbp:eliminationHalfLife
|
2–3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasEnantiomer
|
gptkb:dexmethylphenidate
gptkb:levomethylphenidate
|
|
gptkbp:hasMolecularFormula
|
C14H19NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methylphenidate
|
|
gptkbp:interactsWith
|
gptkb:tricyclic_antidepressants
gptkb:monoamine_oxidase_inhibitors
antihypertensive drugs
|
|
gptkbp:IUPACName
|
methyl 2-phenyl-2-(piperidin-2-yl)acetate
|
|
gptkbp:KEGGID
|
D08167
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
dopamine reuptake inhibitor
|
|
gptkbp:MeSH_ID
|
D008687
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
233.31 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
4015
4158
CHEMBL416
DB00422
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
intravenous
|
|
gptkbp:sideEffect
|
abdominal pain
headache
loss of appetite
increased heart rate
nervousness
insomnia
dry mouth
|
|
gptkbp:UNII
|
207R9A8QOL
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Ritalin
|
|
gptkbp:bfsLayer
|
5
|